Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jazz Pharmaceuticals achieves record revenue in Q4 2022

Jazz Pharmaceuticals delivered strong financial performance in Q4 2022, driven by key products and a focus on operational efficiency.
The company's pipeline expansion, strategic focus, and differentiated products position it well for future growth.
While facing challenges in sales guidance and market education, Jazz Pharmaceuticals has opportunities for growth through new molecules and market expansion.
Overall, Jazz Pharmaceuticals remains optimistic about its growth trajectory, supported by product differentiation and strategic initiatives.

Jazz Pharmaceuticals excels in Q1 2023, eyes growth opportunities

Jazz Pharmaceuticals demonstrated strong financial performance and operational excellence in Q1 2023, driven by key products like Xywav and Epidiolex.
While facing challenges in patient adoption and prescriber education, the company remains focused on strategic investments and sustainable growth initiatives.
With a robust pipeline, revenue growth opportunities, and a commitment to patient impact, Jazz Pharmaceuticals is well-positioned to achieve its Vision 2025 goals.

Jazz Pharmaceuticals excels in Q2, eyes pipeline growth opportunities

Jazz Pharmaceuticals demonstrated strong commercial performance and financial growth in Q2 2023, driven by key product successes and pipeline advancements.
While facing operational challenges, the company's strategic strengths in capital allocation, R&D focus, and market positioning bode well for future growth.
With a clear focus on Vision 2025 targets, Jazz Pharmaceuticals remains confident in its ability to navigate challenges and capitalize on growth opportunities.

Jazz Pharmaceuticals reports strong Q3 performance and eyes global expansion

Jazz Pharmaceuticals' Q3 earnings call reflects robust sales growth, strategic initiatives to drive key products towards blockbuster status, and a focus on innovation in therapeutic treatments.
The company's strengths in revenue diversification, global expansion plans for Epidiolex, and confidence in upcoming treatments position it well for sustained growth in the pharmaceutical market.
While facing challenges in market competition and revenue dynamics, Jazz Pharmaceuticals is poised to capitalize on opportunities in global market expansion, new oncology assets, and innovative treatment approaches.

Jazz Pharmaceuticals excels in Q4, eyes growth through innovation

Jazz Pharmaceuticals delivered strong financial results, driven by key products like Xywav, Epidiolex, and Rylaze, showcasing revenue growth and profitability.
The company's focus on oncology and neuroscience, with late-stage catalysts and global expansion plans, highlights a commitment to innovation and market leadership.
While facing challenges in a competitive landscape, Jazz Pharmaceuticals remains poised for growth through strategic initiatives, R&D advancements, and product differentiation.
Overall, Jazz Pharmaceuticals' performance, strengths, and opportunities position it well for sustained growth and value creation in the pharmaceutical industry.

Jazz Pharma excels in Q1 2024, eyes growth in oncology and neuroscience

Jazz Pharmaceuticals delivered strong Q1 2024 results, driven by revenue growth and key product performance in oncology and neuroscience.
The company's disciplined capital allocation and strategic investments position it well for future growth and innovation in its pipeline.
While facing challenges in clinical trials and competitive markets, Jazz Pharma remains focused on leveraging strengths and seizing growth opportunities.

Jazz Pharmaceuticals achieves record revenues, updates guidance for 2024

Jazz Pharmaceuticals delivered exceptional financial performance in Q2 2024 with record revenues.
Key products showed strong sales growth, reflecting market acceptance and demand.
The company's focus on long-term value creation through investments and guidance update is notable.
Challenges include maintaining growth momentum and successful data readouts from late-stage programs.

Jazz Pharmaceuticals excels in Q3 with record sales and growth

Jazz Pharmaceuticals' Q3 2024 performance reflects strong revenue growth and operational resilience, driven by key products and ongoing innovation efforts.
While facing challenges like revenue impact for Rylaze, the company remains focused on normalizing demand and advancing its pipeline programs.
With a solid financial foundation and a strategic focus on high-potential areas, Jazz Pharmaceuticals is well-positioned to capitalize on growth opportunities.
By affirming revenue guidance, investing in innovation, and exploring business development prospects, Jazz Pharmaceuticals demonstrates a commitment to long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz Pharma's (JAZZ) product revenues grow in the third quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.

Jazz Pharma (JAZZ) Q3 Earnings Beat, New Drugs Drive Sales

FedEx

Kinross Gold

MarketAxess Holdings

Peloton

RPM International

Constellation Brands

It's just as important to know what stocks to sell as it is to know what stocks to buy. These stocks are prime examples of stocks to drop now.

7 F-Rated Stocks to Sell Before We Reach Christmas

Jazz Pharmaceuticals PLC (JAZZ) CEO Bruce Cozadd on Q3 2021 Results - Earnings Call Transcript

Jazz (JAZZ) delivered earnings and revenue surprises of 28.44% and 0.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (JAZZ) Tops Q3 Earnings and Revenue Estimates

Jazz Pharmaceuticals plc (NASDAQ:JAZZ), a global biopharmaceutical company, announced its financial results Tuesday afternoon for the third quarter of 2021 and updated financial guidance for 2021.

Jazz Pharmaceuticals Reports Q3 Financial Results, Raises Full-Year Earnings Guidance

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

Jazz Pharmaceuticals: Q3 Earnings Insights

DUBLIN, Nov. 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2021 and updated financial guidance for 2021. "Last year, we set the ambitious corporate objective of completing five key commercial launches through 2020 and 2021.

Jazz Pharmaceuticals Announces Third Quarter 2021 Financial Results And Raises Full Year Earnings Guidance

DUBLIN, Nov. 4, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 16 new data abstracts from across its hematology/oncology development program will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting, which will be held December 11-14, 2021. This includes five presentations from investigator-sponsored trials and three presentations from collaboration studies with The University of Texas MD Anderson Cancer Center (MD Anderson).

Jazz Pharmaceuticals to Present Data Showcasing Clinical Advances Across Hematology/Oncology at ASH 2021 Annual Meeting

Zynga

There's plenty of growth on the horizon for these stocks, which are trading near their lows for the year.

2 Top Growth Stocks to Buy Heading Into November

Dollar Tree

Omega Healthcare Investors

Paysafe

Vale S.A.

Identifying stocks to buy on the dip has proved to be a winning strategy for long-term investors over the past decade. The post 7 Top Stocks to Buy On Any Dip If You Get the Chance in Q4 appeared first on InvestorPlace.

7 Top Stocks to Buy On Any Dip If You Get the Chance in Q4

DUBLIN, Oct. 26, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 third quarter financial results on Tuesday, November 9, 2021 after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.

Jazz Pharmaceuticals to Report 2021 Third Quarter Financial Results on November 9, 2021

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline

Novavax

Viatris

Analysts are bullish about these bargains.

3 Dirt-Cheap Stocks Wall Street Thinks Will Soar 43% to 80%

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Jazz (JAZZ) Beat Estimates Again in Its Next Earnings Report?

Shares of Jazz Pharmaceuticals have been under pressure in the last few months on what appears to be investor concern about the durability of the company's narcolepsy franchise.

Jazz Pharmaceuticals: Narcolepsy Franchise Concerns Weigh On Investor Sentiment

Innovative Industrial Properties

Is Now The Time To Add To Your Long Term Portfolio? The post Best Marijuana Stocks To Watch For Your Long Term Portfolio Right Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Best Marijuana Stocks To Watch For Your Long Term Portfolio Right Now

The Securities and Exchange Commission has charged a former Goldman Sachs (NYSE: GS) compliance analyst with using confidential information to generate over $471,000 in ill-gotten gains. The suit alleges that Jose Luis Casero Sanchez made more than $70,000 by using the information on Jazz Pharmaceuticals Plc's (NASDAQ: JAZZ) acquisition of G.W.

SEC Charges Former Goldman Sachs Officer For Insider Trading On 2 M&A Deals

Activision Blizzard

Alibaba

Get these stocks while they're near their 52-week lows.

September Sell-Off: 3 Dirt Cheap Growth Stocks to Buy

Scotts Miracle-Gro

Top Cannabis Stocks To Watch Mid-September The post Are These 2 Top Cannabis Stocks On Your List For September? 2 To Watch For Your Long Term Portfolio appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Are These 2 Top Cannabis Stocks On Your List For September? 2 To Watch For Your Long Term Portfolio

DUBLIN, Sept. 13, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast on Wednesday, October 13, 2021 at 4:30 p.m.

Jazz Pharmaceuticals Announces Xywav® (calcium, magnesium, potassium, and sodium oxybates) Investor Webcast on October 13, 2021

2 Marijuana Stocks To Watch This Month For Better Trading The post 2 Marijuana Stocks To Watch At The Beginning Of September 2021 appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

2 Marijuana Stocks To Watch At The Beginning Of September 2021

Moderna

Zogenix

These fast-paced companies should generate jaw-dropping revenue growth over the next three years.

3 Hypergrowth Stocks Expected to Increase Sales 1,185% to 12,629% by 2023

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Jazz (JAZZ) Down 14.1% Since Last Earnings Report: Can It Rebound?

Ascendis Pharma

Cara Therapeutics

Sesen Bio Inc.

Sanofi

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – a measure of innovation in the biopharma sector – numbered four for the month, taking the total for the year to 36, two less than relative to the same period in 2020.

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

Health Canada has approved Jazz Pharmaceuticals plc's (NASDAQ: JAZZ) Sunosi (solriamfetol) for excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA) in adult patients.  Once-daily Sunosi is approved with doses of 75 mg and 150 mg.

News for Jazz Pharmaceuticals Stock (JAZZ)